Related Experiment Video
Updated: Aug 13, 2025
Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination
Published on: September 25, 2014
Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine
James Z Deng1, Nathan Kuster2, Ashley Drumheller2
1Vaccine Analytical Research & Development, Analytical Research & Development, MRL, Merck & Co., Inc., Rahway, NJ, USA. james_deng@merck.com.
Abstract:
Bacterial infection remains as one of the major healthcare issues, despite significant scientific and medical progress in this field. Infection by Streptococcus Pneumoniae (S. Pneumoniae) can cause pneumonia and other serious infectious diseases, such as bacteremia, sinusitis and meningitis. The pneumococcal capsular polysaccharides (CPS) that constitute the outermost layer of the bacterial cell are the main immunogens and protect the pathogen from host defense mechanisms. Over 90 pneumococcal CPS serotypes have been identified, among which more than 30 can cause invasive pneumococcal diseases that could lead to morbidity and mortality. Multivalent pneumococcal vaccines have been developed to prevent diseases caused by S. Pneumoniae. These vaccines employ either purified pneumococcal CPSs or protein conjugates of these CPSs to generate antigen-specific immune responses for patient protection. Serotype-specific quantitation of these polysaccharides (Ps) antigen species are required for vaccine clinical dosage, product release and quality control. Herein, we have developed an antibody-enhanced high-performance liquid chromatography (HPLC) assay for serotype-specific quantitation of the polysaccharide contents in multivalent pneumococcal conjugate vaccines (PCVs). A fluorescence-labeled multiplex assay format has also been developed. This work laid the foundation for a serotype-specific antigen assay format that could play an important role for future vaccine research and development.
Insights
Quantifying Streptococcus pneumoniae polysaccharide antigens is crucial for vaccine development. This study introduces an antibody-enhanced HPLC assay for precise serotype-specific measurement in pneumococcal conjugate vaccines (PCVs).
Area of Science:
- Immunology and Vaccinology
- Microbiology and Infectious Diseases
- Analytical Chemistry
Background:
- Bacterial infections, particularly those caused by Streptococcus pneumoniae (S. pneumoniae), remain a significant global health concern, leading to severe diseases like pneumonia, meningitis, and bacteremia.
- Pneumococcal capsular polysaccharides (CPS) are key virulence factors and immunogens; over 90 serotypes exist, with more than 30 causing invasive diseases.
- Multivalent pneumococcal conjugate vaccines (PCVs) are vital for prevention, utilizing CPS or their protein conjugates to elicit protective immune responses.
Purpose of the Study:
- To address the need for accurate serotype-specific quantitation of polysaccharide (Ps) antigens in multivalent pneumococcal conjugate vaccines (PCVs).
- To develop and validate novel analytical methods for quality control and dosage determination of PCVs.
- To establish a foundation for future vaccine research and development through advanced antigen assay formats.
Main Methods:
- Development of an antibody-enhanced high-performance liquid chromatography (HPLC) assay for precise serotype-specific quantification of pneumococcal polysaccharide antigens.
- Implementation of a fluorescence-labeled multiplex assay format for enhanced detection and analysis.
- Application of the developed assay for the analysis of polysaccharide content in multivalent pneumococcal conjugate vaccines.
Main Results:
- Successfully developed and demonstrated an antibody-enhanced HPLC assay capable of serotype-specific quantitation of polysaccharide antigens in PCVs.
- Established a fluorescence-labeled multiplex assay format, offering a sensitive and specific analytical tool.
- Validated the assay's utility for critical applications in vaccine clinical dosage, product release, and quality control.
Conclusions:
- The developed antibody-enhanced HPLC assay provides a robust method for serotype-specific quantitation of pneumococcal polysaccharides in PCVs.
- This assay technology is essential for ensuring the quality, safety, and efficacy of pneumococcal vaccines.
- The established assay format represents a significant advancement for future pneumococcal vaccine research and development.
